PIK3CB and neoplasm: The efficacy of the dual PI3K/HDAC inhibitor fimepinostat (CUDC-907) is also currently being assessed clinically in various solid tumor types and although this does not currently include patients with prostate cancer, fimepinostat is reported to reduce tumor growth in the PTEN-deficient LuCaP 35CR PDX CRPC model [184,185].